Carlsmed enrolls 1st patients in personalized spine surgery study

The first patients have been enrolled in a clinical trial evaluating the outcomes of patients who underwent spine surgery with aprevo, Carlsmed’s patient-specific spine implant.

Advertisement

The study, known as “Compass” — clinical outcome measures in personalized aprevo spine surgery —  is a multicenter post-market prospective observational registry that will collect data on patients treated with aprevo devices and track outcomes over two years.

The study will assess spinal alignment, complications and patient-reported outcome measures for a variety of patients with degenerative spinal conditions.

“The Compass study will generate first-of-its-kind preoperative intervertebral data for surgical planning and personalized aprevo designs along with postoperative metrics for spinal alignment and clinical outcomes,” Roland Kent, MD, chief investigator of the study, said in an Oct 11 news release. “After observing excellent initial results with aprevo in my own patients, I am excited to collaborate with colleagues across the country to verify durability of achieved spinal alignment and assess patient satisfaction over the next two years.”

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Is ambulatory care healthcare’s big margin engine? 4 leaders weigh in

Wednesday, July 29
1:00 PM - 2:00 PM CDT

Presenters: Joe Ganley, athenahealthJeffrey Flynn, CASC, Gramercy Surgery CenterBryan Tsao, Access Center, Loma Linda University HealthJason Zepeda, Northridge Hospital Medical Center, CommonSpirit HealthGreg DeConciliis, PA-C, CASC, Boston Out­Patient Surgical Suites

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.